Product Description
ANAVEX 3-71 is being developed by Anavex Life Sciences Corp for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases. (Sourced from: https://www.anavex.com/post/anavex-announces-long-lasting-effect-of-anavex-3-71-preventing-cognitive-decline-in-a-transgenic-rat)
Mechanisms of Action: S1R Agonist, M1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Anavex Life Sciences Corp.
Company Location: Eastern America
Company CEO: Christopher Missling
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Anavex Life Sciences Corp. presented P2 Schizophrenia results on 2025-10-02 for ANAVEX 3-71
- Clinical Outcomes Reported - Anavex Life Sciences Corp. announced they will present P2 Schizophrenia results in 2H25 for ANAVEX 3-71
- Clinical Outcomes Reported - Anavex Life Sciences Corp. presented P1 Alzheimer Disease|Dementia|Frontotemporal Dementia|Schizophrenia results on 2024-01-24 for ANAVEX 3-71
Highest Development Phases
Phase 2: Schizophrenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06245213 |
SZ-001 | P2 |
Active, not recruiting |
Schizophrenia |
2025-06-30 |
2% |
2025-05-06 |
Primary Endpoints |